New Horizons in the Management of Alzheimer's Disease:
Advances in Early Diagnosis & Treatment Strategies

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session at the 2017 Fall Forum. If you participated in
the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from January 20, 2018 to January 31, 2019

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from
Biogen and Lilly USA LLC

Alzheimer’s disease is the most common form of dementia, affecting an estimated 5 million people in the United States. It is a cognitive disorder that includes behavioral impairment that interferes with social and occupational functioning. Over time the disease destroys large areas of the brain, resulting in cellular loss and dysfunction, a gradual loss of memory, problems with reasoning or judgment, disorientation, difficulty in learning, loss of language skills, and decline in the ability to perform routine tasks. Currently, an autopsy or brain biopsy is the only way to make a definitive diagnosis of Alzheimer’s disease. In clinical practice, the diagnosis is typically made on the basis of the history and findings on Mental Status Examination. There is no single test that can show whether a person has Alzheimer's. While physicians can almost always determine if a person has dementia, it may be difficult to determine the exact cause. Diagnosing Alzheimer's requires careful medical evaluation, including medical history, mental status testing, physical and neurological exam, blood tests and brain imaging.

The importance of early diagnosis cannot be understated. As the use of biomarkers continues to grow, the potential for catching Alzheimer’s disease even earlier is crucial to improving outcomes. Today, there is no treatment that can reverse the disease, and all the available treatments to Alzheimer’s are symptomatic therapies. The standard medical treatments include cholinesterase inhibitors, a partial N -methyl-D-aspartate (NMDA) antagonist and memantine, which helps with brain cell communication. However, advances in the science underlying Alzheimer’s are also emerging at a rapid rate, while a large number of potential agents are undergoing clinical trials. Many of these new therapies are based on an understanding of the pathogenesis of Alzheimer's disease, and are designed to try to either slow or halt the progression of the disease. Therapies directed against some aspect of beta-amyloid formation, against neurofibrillary tangle formation and against the inflammatory response are all considered, as are the problems associated with each area.

Upon Completion of this activity, participants will be able to:

  • Analyze the current evidence and clinical data for the selection of appropriate therapies for the treatment of early Alzheimer’s disease symptoms

  • Examine the use of biomarkers to diagnose Alzheimer’s disease and the benefits that early diagnosis will achieve

  • Evaluate the safety and efficacy of new treatment options to improve the pathophysiology and management strategies for pre-symptomatic Alzheimer’s disease

  • Identify current and emerging treatment options that can achieve new therapeutic targets in Alzheimer’s patients, including those who do not respond to traditional therapies

Faculty: Marwan Noel Sabbagh, MD, FAAN
Karsten Solheim Chair for Dementia
Professor of Neurology
Director of the Alzheimer’s and Memory Disorders Division
Barrow Neurological Institute
Dignity Health
St. Joseph Health and Medical Center


Dr. Sabbagh acts as a consultant to Axovant, Biogen, Grifols, Lilly Pharmaceuticals, Sanofi and vTv Therapeutics. He also receives research support from Avid Pharmaceuticals, Axovant, Biogen, Genentech, Lilly Pharmaceuticals, Merck, Pfizer, Roche Diagnostics Corporation, Suven, and vTv Therapeutics. He also owns and self manages stock with Brain Health, Muse Labs and Versanum. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jeremy Williams has no real or perceived financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by an educational grant from
Biogen and Lilly USA LLC

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue